Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization.
5-FU
Actinic keratosis
Chemical peels
Cutaneous field cancerization
Photo-carcinogenesis
Photoaging
Photodynamic therapy
Photolyase
Sunscreens
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
04
06
2020
pubmed:
19
7
2020
medline:
19
7
2020
entrez:
19
7
2020
Statut:
ppublish
Résumé
Field cancerization (FC) is a chronic disease involving multiple clinical and subclinical actinic keratoses (AK) on large photo-exposed surfaces with multifocal areas of dysplasia and precancerous changes. Patients and treatment must be properly monitored and managed to avoid aggravation and progression of the disease. Management of actinic keratoses includes lesion-directed treatments, such as cryotherapy and field-directed therapies. Field-directed therapies may have the potential to address subclinical damage, reduce AK recurrence rates and potentially reduce the risk of squamous cell carcinoma development. Multiple studies have demonstrated the efficacy of field-directed treatments, including 5-fluorouracil, photodynamic therapy, imiquimod, chemical exfoliation with trichloroacetic acid and diclofenac gel, for multiple AK and FC. The choice of therapy should be based on multiple factors, such as efficacy, tolerability, patient risk profile, costs and cosmetic results. Management of AK includes not only treatment but also prevention. Medical devices, such as sunscreens containing liposome-encapsulated DNA repair enzymes, can repair DNA damage associated with chronic UV radiation and reduce the number of new AK lesions. Here we provide therapeutic pearls and expert opinions on the treatment of AK and FC (as monotherapy or in combination) with the overall aim to achieve better, faster, and well-tolerated clinical responses.
Identifiants
pubmed: 32681454
doi: 10.1007/s13555-020-00425-4
pii: 10.1007/s13555-020-00425-4
pmc: PMC7477025
doi:
Types de publication
Journal Article
Langues
eng
Pagination
903-915Subventions
Organisme : ISDIN Labs (ES)
ID : Publication costs are supported by ISDIN
Références
Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1 Pt 2):23–4.
pubmed: 10607353
Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017;31(Suppl 2):5–7.
pubmed: 28263020
Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; Clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.
pubmed: 13094644
Willenbrink TJ, Ruiz ES, Cornejo C, Schmults CD, Arron S, Jambusaria-Pahlajani A. Field cancerization: definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol. 2020;S0190-9622(20)30791-X. https://doi.org/10.1016/j.jaad.2020.03.126 .
Jetter N, Chandan N, Wang S, Tsoukas M. Field cancerization therapies for management of actinic keratosis: a narrative review. Am J Clin Dermatol. 2018;19:543–57.
pubmed: 29582369
Longo I, Serra-Guillén C. Quality of life, behaviour and attitudes towards actinic keratosis in Spain: the PIQA study. Actas Dermosifiliogr. 2018;109:331–9.
pubmed: 29477269
Kopera D. Earliest stage treatment of actinic keratosis with imiquimod 3.75% cream: two case reports-Perspective for non melanoma skin cancer prevention. Dermatol Ther. 2020;e13517. https://doi.org/10.1111/dth.13517 .
Navarrete-Dechent C, Marghoob AA, Marchetti MA. Contemporary management of actinic keratosis. J Dermatol Treat. 2019;1–3. https://doi.org/10.1080/09546634.2019.1682504 .
Philipp-Dormston WG, Battistella M, Boussemart L, Di Stefani A, Broganelli P, Thoms KM. Patient-centered management of actinic keratosis. Results of a multi-center clinical consensus analyzing non-melanoma skin cancer patient profiles and field-treatment strategies. J Dermatolog Treat. 2019;1–7. https://doi.org/10.1080/09546634.2019.1679335 .
Christensen SR. Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas. F1000Research. 2018;7:F1000. https://doi.org/10.12688/f1000research.12837.1 .
doi: 10.12688/f1000research.12837.1
pubmed: 29904586
pmcid: 5989149
Puig S, Granger C, Garre A, et al. Review of clinical evidence over 10 years on prevention and treatment of a film-forming medical device containing photolyase in the management of field cancerization in actinic keratosis. Dermatol Ther (Heidelb). 2019;9:259–70.
Puig-Butillé JA, Malvehy J, Potrony M, et al. Role of CPI-17 in restoring skin homoeostasis in cutaneous field of cancerization: effects of topical application of a film-forming medical device containing photolyase and UV filters. Exp Dermatol. 2013;22:494–6.
pubmed: 23800065
pmcid: 3748792
Navarrete-Dechent C, Molgó M. The use of a sunscreen containing DNA-photolyase in the treatment of patients with field cancerization and multiple actinic keratoses: a case-series. Dermatol Online J. 2017;23(1):13030/qt5zc6085s.
pubmed: 28329483
Eibenschutz L, Silipo V, De Simone P, et al. A 9-month, randomized, assessor-blinded, parallel-group study to evaluate clinical effects of film-forming medical devices containing photolyase and sun filters in the treatment of field cancerization compared with sunscreen in patients after successful photodynamic therapy for actinic keratosis. Br J Dermatol. 2016;175(6):1391–3.
pubmed: 27167413
Vaño-Galván S, Jiménez N, Grillo E, Ballester A. An observational study on the effectiveness and safety of the combination of a topical product containing photolyase and cryotherapy in patients with actinic keratoses in clinical practice. Piel. 2016;31(8):532–6 [in Spanish].
Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380:935–46.
pubmed: 30855743
Gupta AK, Paquet M. Network meta-analysis of the outcome ‘participant complete clearance’ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013;169:250–9.
pubmed: 23550994
Weinstock MA, Thwin SS, Siegel JA, et al. Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial. JAMA Dermatol. 2018;154:167–74.
pubmed: 29299592
pmcid: 5839275
Yoon J, Phibbs CS, Chow A, et al. Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis. J Am Acad Dermatol. 2018;79:501–507.e2.
pubmed: 29505863
Morton CA, Szeimies R-M, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications—actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27:536–44.
pubmed: 23181594
Gholam P, Denk K, Sehr T, et al. Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. J Am Acad Dermatol. 2010;63:213–8.
pubmed: 20538367
Gholam P, Fink C, Bosselmann I, Enk AH. Retrospective analysis evaluating the effect of a keratolytic and physical pretreatment with salicylic acid, urea and curettage on the efficacy and safety of photodynamic therapy of actinic keratoses with methylaminolaevulinate. J Eur Acad Dermatol Venereol. 2016;30:619–23.
pubmed: 26508040
Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol. 1981;77:13–9.
pubmed: 7252245
Wolf P. Ablative fractional laser-fortified daylight photodynamic therapy may be the patient’s preferred choice for the treatment of field cancerization. Br J Dermatol. 2019;180:697–8.
pubmed: 30933335
Lev-Tov H, Larsen L, Zackria R, et al. Microneedle-assisted incubation during aminolaevulinic acid photodynamic therapy of actinic keratoses: a randomized controlled evaluator-blind trial. Br J Dermatol. 2017;176:543–5.
pubmed: 27730625
Petukhova TA, Hassoun LA, Foolad N, et al. Effect of expedited microneedle-assisted photodynamic therapy for field treatment of actinic keratoses: a randomized clinical trial. JAMA Dermatol. 2017;153:637–43.
pubmed: 28514458
pmcid: 5543325
Steeb T, Wessely A, Leiter U, French LE, Berking C, Heppt MV. The more the better? An appraisal of combination therapies for actinic keratosis. J Eur Acad Dermatol Venereol. 2020;34(4):727–32.
pubmed: 31587385
Nissen CV, Heerfordt IM, Wiegell SR, et al. Pretreatment with 5-fluorouracil cream enhances the efficacy of daylight-mediated photodynamic therapy for actinic keratosis. Acta Derm Venereol. 2017;97:617–21.
pubmed: 28093604
Mei X, Wang L, Zhang R, Zhong S. Daylight versus conventional photodynamic therapy for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. Photodiagnosis Photodyn Ther. 2019;25:23–8.
pubmed: 30412779
Heerfordt IM, Wulf HC. Daylight photodynamic therapy of actinic keratosis without curettage is as effective as with curettage: a randomized clinical trial. J Eur Acad Dermatol Venereol. 2019;33(11):2058–61.
pubmed: 31197894
Pagliaro J, Elliott T, Bulsara M, King C, Vinciullo C. Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen’s disease: an effective addition to treatment: a pilot study. Dermatol Surg. 2004;30(1):63–6.
pubmed: 14692930
Wiegell SR, Petersen B, Wulf HC. Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. Br J Dermatol. 2014;171(6):1487–92.
pubmed: 25060803
Bylka W, Znajdek-Awiżeń P, Studzińska-Sroka E, et al. Centella asiatica in dermatology: an overview. Phytother Res. 2014;28:1117–24.
pubmed: 24399761
Wiegell SR, Haedersdal M, Wulf HC. Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study. Acta Derm Venereol. 2009;89:145–9.
pubmed: 19325998
Halldin CB, Paoli J, Sandberg C, et al. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol. 2009;160:795–800.
pubmed: 19210497
Dika E, Fanti PA, Lambertini M, et al. Cutaneous squamous cell carcinoma progression during imiquimod treatment. J Am Acad Dermatol. 2018;79(1):e11–e12.
pubmed: 29908822
Serra-Guillén C, Nagore E, Llombart B, et al. A 12-day course of imiquimod 5% for the treatment of actinic keratosis: effectiveness and local reactions. Actas Dermosifiliogr. 2018;109:248–53.
pubmed: 29246367
Sidiropoulou P, Gregoriou S, Rigopoulos D, Kontochristopoulos G. Chemical peels in skin cancer: a review. J Clin Aesthet Dermatol. 2020;13:53–7.
pubmed: 32308785
pmcid: 7158909
Fischer TC, Perosino E, Poli F, et al. Chemical peels in aesthetic dermatology: an update 2009. J Eur Acad Dermatol Venereol. 2010;24:281–92.
pubmed: 19744174
de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176:20–43.
pubmed: 28098380
López Martín-Prieto S, Sánchez Conejo-Mir J. Peeling químico con ácido tricloroacético. Un peeling clásico de máxima actualidad. Actas Dermosifiliogr. 2001;92:537–47.
Kaminaka C, Yamamoto Y, Yonei N, et al. Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: prospective pilot trial with assessment of clinical, histologic, and immunohistochemical correlations. J Am Acad Dermatol. 2009;60:615–25.
pubmed: 19293009
Holzer G, Pinkowicz A, Radakovic S, et al. Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis. Br J Dermatol. 2017;176:1155–61.
pubmed: 28012181
Goldberg DJ. Case-based experience in the use of 5-fluorouracil cream 0.5% as monotherapy and in conjunction with glycolic acid peels for the treatment of actinic keratosis. J Cosmet Laser Ther. 2010;12:42–6.
pubmed: 20085453
Ayati Z, Amiri MS, Ramezani M, Delshad E, Sahebkar A, Emami SA. Phytochemistry, traditional uses and pharmacological profile of rose hip: a review. Curr Pharm Des. 2018;24(35):4101–24.
pubmed: 30317989
Granger C, Aladren S, Delgado J, et al. Prospective evaluation of the efficacy of a food supplement in increasing photoprotection and improving selective markers related to skin photo-ageing. Dermatol Ther (Heidelb). 2020;10:163–78.
Herold M, Good AJ, Nielson CB, Longo MI. Use of topical and systemic retinoids in solid organ transplant recipients: update and review of the current literature. Dermatol Surg. 2019;45(12):1442–9.
pubmed: 31403546
Bettoli V, Zauli S, Virgili A. Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how. J Dermatol Treat. 2013;24:235–7.
Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373:1618–26.
pubmed: 26488693
Schmitz L, Gambichler T, Gupta G, et al. Actinic keratosis area and severity index (AKASI) is associated with the incidence of squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2018;32:752–6.
pubmed: 29117441
López Estebaranz JL, Pampín Franco A, Gamo Villegas R, Floristán U. Monitoring ingenol mebutate gel treatment of actinic keratoses by reflectance confocal microscopy. Acta Derm Venereol. 2017;97:646–8.
pubmed: 28093603